Peter S. Nelson

TL;DR: A novel immunohistochemical approach was developed which was used to ascertain the prevalence of AR variants in a large number of primary PCa and metastatic CRPC tissues and showed a snapshot of overall high frequency of C-terminal truncated AR splice variants and site specific AR loss in CRPC, which could have utility in stratifying patients for AR targeted therapeutics.

TL;DR: It is demonstrated that AR-V7 protein is rarely expressed in primary PC but is frequently detected following androgen deprivation therapy, with further significant increase in expression following abiraterone acetate or enzalutamide therapy, which provides impetus to develop therapies that abrogate AR-v7 signaling.

TL;DR: Divergence between the two data types was most frequently seen for genes whose array signals exceeded background but lacked immunoreactivity by immunostaining, and agreement between these two very different methodologies has great implications for their respective use in both molecular studies and clinical trials employing molecular biomarkers.

TL;DR: The findings highlight the complex genomic structure of mCRPC, nominate alterations that may inform prostate cancer treatment, and suggest that additional recurrent events in the non-coding m CRPC genome remain to be discovered.

TL;DR: This work finds that 12% (7 of 60) of advanced prostate cancers are hypermutated, and that all hyperMutated cancers have mismatch repair gene mutations and microsatellite instability (MSI).